Browsing Tag
Swedish Orphan Biovitrum AB
4 posts
How the VALIANT Phase 3 data may strengthen EMPAVELI’s nephrology market position
Find out how Sobi’s VALIANT Phase 3 data may reshape EMPAVELI’s nephrology market position and what it means for rare kidney disease growth.
EMBRACE results prompt Sobi to engage regulators on emapalumab sepsis pathway
Sobi will advance emapalumab in IFNγ-driven sepsis after EMBRACE trial shows proof-of-concept. Find out what this pivot means for its strategy and the field.
Ionis and SOBI’s olezarsen cuts pancreatitis risk by 85% in sHTG phase 3 trials
Olezarsen showed 85% reduction in acute pancreatitis for severe hypertriglyceridemia. See what this means for Sobi, Ionis, and upcoming EMA and FDA filings.
Will NASP transform gout care in 2026? Sobi’s biologic therapy heads for FDA decision
Sobi’s NASP for uncontrolled gout advances to FDA review with June 2026 PDUFA date. Find out how this novel therapy could reshape gout treatment.